Observational studyNeuroradiology2026
Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series.
Observational study in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeStent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms. MATERIALS AND
methodsThis independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed.
resultsNinety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I-II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days).
conclusionsThe pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.
Indexed as
Identifiers
41410872What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.